6
Participants
Start Date
April 23, 2019
Primary Completion Date
July 5, 2019
Study Completion Date
July 5, 2019
14C-PF-06651600
Oral solution of 200 mg 14C labeled PF-06651600 containing approximately 300 nCi radioactivity
14C-PF-06651600 IV
IV solution 60 micrograms of 14C labeled PF-06651600 containing approximately 300 nCi radioactivity
PF-06651600
Oral solution 200mg
PRA Health Sciences, Groningen
PRA Health Sciences Utrecht, Utrecht
Lead Sponsor
Pfizer
INDUSTRY